Naslov
P27KIP1 in acute myeloid leukemia

Autori
Sučić, Mirna ; Hodak, Nataša ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov Kuveždić, Koraljka ; Labar, Boris

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Hematologica / Cazzola, Mario - Pavia : Ferrata-Starti Foundation, 2010, 506-506

Skup
15th Congress of the European Hematology Association

Mjesto i datum
Barcelona, Španjolska, 10.06.2010. - 13.06.2010

Vrsta sudjelovanja
Ostalo

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
acute leukemia; P27KIP1

Sažetak
Acute leukemia (AL) is clonal proliferation of immature leukemia cells in bone marrow (BM, peripheral blood and other tissue. Uncontrolled clonal proliferation caused by malignant transformation of cells is a result of many alterations of cell functions, involved in cell proliferation, differentiation and apoptosis. Malignant transformation of leukemic cells is also associated with altered activity of cyclin dependent kinases (CDKs) and cyclin-dependent kinase inhibitors CKIs. CDKs form periodically complexes with cyclins and induce cell cycle progression from G1 to S phase. One of CKIs is p27Kip1 member of KIP (kinase inhibitor proteins) family. Aim of this study was to analyze p27Kip1 immunocytochemical expression of BM hematopoietic cells (HCs) in AML patients before cytostatic therapy and in 11 control group of patients. Methods: microscopic analysis of p27Kip1 positive HCs was done after immunocytochemical APAAP staining of BM smears. Analyses were done in 14 AML patients and 11 patients of control group (not suffering of hematological malignant disease). BM analysis in control group was done in course of standard diagnostics and from all patients in both groups informed consent was obtained. Results: median (8%) and upper limit (45%) of percentages of p27Kip1 positive HCs in control group were higher than same parameters in leukemic cells (median: 2, 3% ; upper limit 18%). Moreover, percentages of p27Kip1 positive HCs in control group were significantly higher (p<0.001) than in AML patients. In 2 out of 14 AML patients was found higher percentage of p27Kip1 positive HCs (5%, 18%). Conclusions: Results of this study point to lower expression pf p27 in AML leukemic cells in comparison to normal hematopoietic cells in control group. Observations are in relation with known p27Kip1 function acting as CKIs of cell cycle progression and with other studies findings implicating variability of p27Kip1 immunoexpression in leukemic cells.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA